ambrisentan

Due to competitive concerns with Myogen's ambrisentan, which is expected to enter the market in 2007, timing is of the essence for Encysive.

Big Pharma Bounces On Q2 Earnings 2006

Due to competitive concerns with Myogen's ambrisentan, which is expected to enter the market in 2007, timing is of the essence for Encysive.

Encysive Shares Clouded By Uncertainty 2006

Gilead has a medicine called ambrisentan for the same lung disease in the final stage of human testing generally required for regulatory approval.

Gilead to Buy Arresto Biosciences for $225 Million to Obtain Lung Medicine - Bloomberg 2010

Shares of Myogen fell 10% as investors were disappointed with a recently announced deal with British drug giant GlaxoSmithKline for experimental drug ambrisentan, a treatment for pulmonary arterial hypertension.

Tysabri News Lifts Drug Stocks 2006

Understanding the function of the lung could help in developing other drugs that might fit in with Cayston and ambrisentan.

Gilead's Big Shift Peter Kang 2006

Data on ambrisentan, however, has been very promising; many analysts think the drug can take on Actelion's similar Tracleer.

Gilead's Big Shift Peter Kang 2006

Myogen's lead drug, ambrisentan, is a treatment for a rare disease called pulmonary arterial hypertension, PAH, a blood pressure disorder of the lungs that makes it extremely difficult for patients to breathe.

Gilead's Big Shift Peter Kang 2006

Separately, Myogen said it forged an alliance with British drug giant GlaxoSmithKline for experimental drug ambrisentan, a treatment for pulmonary arterial hypertension.

Eye On Stocks For Tuesday, March 7, 2006Eye On Stocks For Tuesday, March 7 2006

GlaxoSmithKline, which markets Flolan, the current standard-of-care treatment, obtained non-U.S. marketing rights for Myogen's ambrisentan last March in exchange for U.S. rights for Flolan.

Gilead's Big Shift Peter Kang 2006

Myogen's lead drug candidate is ambrisentan, a new type of treatment for pulmonary arterial hypertension, a blood pressure disorder of the lungs.

Buyouts Lift Biotechs 2006